Virbac

Virbac

Virbac

French animal health company


Virbac is a French company dedicated to animal health located in Carros, near Nice. It was founded in 1968 by veterinarian Pierre-Richard Dick.

Quick Facts Company type, Traded as ...

The company is the 6th[1] the largest veterinarian pharmaceutical group with a turnover of 948 million euros in 2020 (59% companion animal and 41% food producing animal). The company is a limited company with a board Euronext Paris stock exchange - compartiment A and is part of the reference index: SBF 120, and eligible SRD, PEA and PEA-PME.

History

Veterinarians Pierre-Richard Dick and Max Rombi founded Virbac (acronym of virology and bacteriology) in 1968 as a veterinary office in the Cap 3000 mall in Nice. The office was sold two years later, after which Dick and Rombi focussed on animal drugs for pets, distinguishing Virbac from large veterinary pharmaceutical companies that specialised in livestock.[2]

At the end of the 1970s, Rombi began the subsidiary Arkovet, from where he developed Arkopharma, specialising in phyto- and nutrition therapy.[2]

International growth

Virbac went international in 1970 with the establishment of offices in Egypt and Spain. Subsidiaries followed in Germany (1982), Italy (1986), Brazil (1987), Australia (1987), Japan (1992), Belgium (1994), Mexico (1998), the United States of America (1999), and Poland (2011).[2]

Pierre-Richard Dick dies at sea at the age of 55. After his death in 1992, his family decided to keep the company.[2]

In January 2015, Virbac finalized the acquisition of two antiparasitic products for 410 million euros from Eli Lilly, which had acquired the veterinary activities of Novartis.[3]

Activities

The company has 4,900 employees and is present in over 100 countries with 33 sales subsidiaries. Its production is located in 10 countries among which France, the US, Mexico, Brazil, Vietnam. It also has eight research and development centers located in the United States, Mexico, Chile, Uruguay, France, Vietnam, Taiwan and Australia.[4] It generates nearly 88% of its revenues outside France.

Its product range is designed to cover the main pathologies in companion animals and livestock: internal and external parasiticides (collars and pipettes), antibiotics, vaccines, diagnostic tests, dog and cat nutrition, dermatology, dental hygiene, reproductive, aquaculture, anesthesia, geriatrics and electronic identification (pets, horses, exotic pets…).


References

  1. "Animal health: Virbac announces 2-digits growth for 2012". 12 March 2013. Retrieved 29 December 2015.
  2. Bloch, Alain; Joseph, Alexandra; Santi, Michel (2010). "Propelled into the future: managing family firm entrepreneurial growth despite generational breakthroughs within family life stage". Transgenerational Entrepreneurship: Exploring Growth and Performance in Family Firms Across Generations. Edward Elgar Publishing. pp. 144–147. ISBN 978-1-84980-546-9.
  3. "Acquisition à 410 millions de $ pour Virbac". LEFIGARO (in French). 2015-01-04. Retrieved 2022-08-20.
  4. "Key figures 2014". Virbac. Retrieved 29 December 2015.

Share this article:

This article uses material from the Wikipedia article Virbac, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.